The most common biomarkers used currently to guide the diagnosis of AD are structural MRI volumetry, cerebrospinal fluid (CSF) tests for Amyloid-β1-42 (Aβ) and Phosphorylated-Tau (P-Tau) concentrations, and PET Aβ imaging; these being used in conjunction with evaluations of cognitive function [1]. Here, MAPT is linked to Alzheimer disease.